Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.970
-0.080 (-7.62%)
At close: Feb 21, 2025, 4:00 PM
0.980
+0.010 (1.02%)
After-hours: Feb 21, 2025, 4:02 PM EST
Akari Therapeutics, Analyst Ratings
Total Analysts
n/a
Consensus Rating
n/a
Price Target
n/a
Upside
n/a
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +2,992.78% | Dec 5, 2022 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +8,147.42% | Nov 1, 2022 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $140 → $100 | Strong Buy | Maintains | $140 → $100 | +10,209.28% | Mar 13, 2020 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $300 → $160 | Strong Buy | Maintains | $300 → $160 | +16,394.85% | Mar 29, 2018 |
| B. Riley Securities | B. Riley Securities | Hold Initiates $60 | Hold | Initiates | $60 | +6,085.57% | Feb 8, 2018 |
| William Blair | William Blair | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Sep 22, 2017 |
| Chardan Capital | Chardan Capital | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | May 31, 2017 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 12, 2017 |
| Chardan Capital | Chardan Capital | Strong Sell Reiterates $100 → $130 | Strong Sell | Reiterates | $100 → $130 | +13,302.06% | Apr 17, 2017 |
| Chardan Capital | Chardan Capital | Strong Sell Initiates $100 | Strong Sell | Initiates | $100 | +10,209.28% | Jul 11, 2016 |